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Abstract: Flupirtine (FLU) is a non-opioid analgesic drug belongs to the 
class of N-Methyl-D-Aspartate (NMDA) antagonist without antipyretic 
or antiphlogistic properties. No analytical method to detect FLU in canine 
plasma samples through a fluorimetric detector has been published to 
date. The analytical method described in this work provides a selective 
and accurate quantification of FLU. The mobile phase consisted of 
ACN:AcONH4 (20 mM) pH 6.8 (60:40, v/v) at a flow rate of 1 mL 
min
−1
 in isocratic mode. Excitation and emission wavelengths were set 
at 323 and 370 nm, respectively. The recoveries of FLU and IS 
(trazodone) were about 89 and 77%. Typical retention times for FLU 
and IS was 4.6±0.2 and 5.8±0.2 min, respectively. Limits of 
quantification and detection were 1 and 0.3 ng/mL, respectively. The 
described method was validated according to international guidelines on 
the bioanalytical method validation. The applicability of this method 
was verified by determining FLU in canine plasma after single oral 
treatment with 5 mg kg
−1
 of Efiret
®
. The low LOQ showed that the 
present method could be useful for the FLU measurement even when 
administered in sub-clinical doses. 
 
Keywords: Flupirtine HPLC-FL, Bioanalytical Method, Dog, Plasma 
Concentration 
 
Introduction 
Flupirtine (FLU), ethyl-N-[2-amino-6-(4-
fluorophenylmethylamino) pyridin-3-yl]carbamate, is a 
triaminopyridine derivative (Fig. 1). It is commercially 
available as a maleate salt because FLU itself is poorly 
water soluble. It is a weak base (pKa 5.3) with weak 
lipophilic features (Klawe and Maschke, 2009). 
FLU is a non-opioid analgesic drug without 
antipyretic or antiphlogistic properties. It is the first drug 
in this unique class within the World Health 
Organization analgesics groupings: The ‘Selective 
Neuronal Potassium Channel Openers’ (SNEPCO) 
(Kornhuber et al., 1999). FLU was first approved in 
Germany 1989 (Singal et al., 2012). The main 
applications of FLU in human medicine are for the 
management of pain following surgery, trauma, dental 
extraction, pain associated with muscle spasms, cancer, 
degenerative joint diseases and conditions such us 
headache and dysmenorrhoea (Harish et al., 2012). FLU 
interacts with a G-protein-regulated channel, namely the 
Inwardly Rectifying K
+
 channels (GIRKs). The GIRKs 
represent a newly recognised family of K
+
 channels distinct 
from the voltage-dependent ones. They are regulated by 
neurotransmitters, occur as different subtypes and are 
variously expressed in different parts of the brain. FLU 
activates GIRKs and stabilizes the membrane resting 
potential by activating potassium channels KCNQ, which 
in turn generates neuronal hyperpolarizing current (M-
current) (Giorgi and Owen, 2012). By increasing the M-
current, FLU is able to decrease neuronal excitability 
(Kolosov et al., 2012). Moreover, FLU inhibits the 
NMDA receptor indirectly by acting as an oxidizing agent 
at the redox site of the NMDA receptor (Singal et al., 
2012), while the Mg
2+ 
block on the NMDA receptor 
remains unchanged (Kornhuber et al., 1999). 
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Fig. 1. Chemical structure of flupirtine: ethyl-N-[2-amino-6-(4-
fluorophenylmethylamino)pyridin-3-yl]carbamate 
 
The unique pharmacological properties of FLU 
contributes to its therapeutic benefits, without undesirable 
adverse effects such as respiratory depression, tolerance 
and dependence that are typical of opioids, or the 
gastrointestinal and renal problems associated with 
non-steroidal antiinflammatory drugs (Devulder, 2010). 
A number of studies also report an important 
superadditive (synergistic) effect between FLU and 
opioid drugs (Kolosov et al., 2012; Capuano et al., 
2011, Lee et al., 2015). 
FLU is rapidly absorbed from the gastrointestinal 
tract in humans (Friedel and Fitton, 1993). It does not 
undergo cytochrome P450 enzyme mediated metabolism 
to a significant extent. The oral and rectal 
bioavailabilities are about 90% and 72.5%, respectively. 
Plasma half-life is in the range 8.5-10.7 h (Niebch et al., 
1992). A single study is present in the literature 
concerning its pharmacokinetics in laboratory species 
(Obermeier et al., 1985). 
Various analytical methods have been developed to 
quantify FLU in biological matrices such as plasma and 
urine from rats and dogs by HPLC-UV and radio-
immunoassay (Obermeier et al., 1985), human plasma and 
urine by HPLC-FL (Niebch et al., 1992; Narang et al., 
1984) and human or rat plasma by LC-MS-MS (Chen et al., 
2001; Zhong et al., 2001; Kandasamy et al., 2011). This 
latter device has also been used for the investigation of the 
in-vitro metabolism of FLU (Methling et al., 2009). 
Recently other methods using HPLC (Kathirvel et al., 
2013) and LC-MS-MS (Zhang et al., 2014) have also been 
developed in FLU based pharmaceutical formulations in 
order to evaluate impurities. 
There is a substantial body of evidence on the 
efficacy of FLU in humans however this is insufficient 
to recommend its off-label use in veterinary clinical 
practice (Giorgi and Owen, 2012). Moreover, nowadays, 
animals (especially pets) are treated as members of the 
family and pet owners demand the same level of care they 
expect for themselves. This change in attitude has resulted 
in a push for the development of more effective and 
innovative veterinary therapy (Giorgi et al., 2012; Giorgi 
and Yun, 2012). Since only one HPLC-UV study has been 
described to detect FLU in canine plasma (Obermeier et al., 
1985), the aim of the present study was to validate a simple, 
accurate and rapid HPLC-FL method for the measurement 
of FLU concentration in canine plasma.  
Materials and Methods 
HPLC-FL 
The HPLC system was an LC Jasco (Como, Italy) 
consisting of quaternary gradient system (PU 980) and 
an in line multilambda fluorescence detector (FP 1520). 
The chromatographic separation assay was performed 
with a Luna C18(2) analytical column (250×4.6 mm inner 
diameter, 5 µ particle size [Phenomenex, Bologna, Italy]) 
preceded by a security guard column with the same 
stationary phase (C18(2) [Phenomenex, Bologna, Italy]). 
The system was maintained at 25°C. The mobile phase 
consisted of ACN:AcONH4 (20 mM) solution, pH 6.8 
(60:40, v/v) at a flow rate of 1 mL/min. A range of buffer 
pH (4.0, 5.0, 6.0 and 6.8) was assayed to optimize the 
chromatographic separation. Excitation and emission 
wavelengths were set at 323 and 370 nm, respectively. The 
elution of the substances was carried out in isocratic mode. 
HPLC-MS 
HPLC-MS Chromatographic separation was 
performed by an Agilent Technologies (Santa Clara, CA, 
USA) 1290 HPLC system which consisted of a high 
pressure pump, auto-sampler and column oven, coupled 
to an Applied Biosystems/Sciex (Foster City, CA, USA) 
API 4000 triple quadrupole mass spectrometer, equipped 
with Turbo V electrospray ionization source (ESI). Main 
parameters were as follows: positive ion mode (Ps); 
ionspray voltage, 5.5 kV; declustering potential, 50 V; 
mass range m/z 100-800 Da; source temperature, 600°C. 
HPLC runs were carried out with the same parameters 
used for HPLC-FL and reported in the previous section. 
Chemical and Reagents 
Pure FLU maleate salt and the Internal Standard 
trazodone (IS) powders (both >99.0% purity) were 
supplied by Sigma-Aldrich (St. Louis, MO,USA). Other 
compounds tested as internal standards were retigabine 
and metoclopramide. They were supplied in powder 
form by Sigma-Aldrich (St. Louis, MO, USA). HPLC 
grade acetonitrile (ACN), methanol (MeOH), 
dichloromethane (CH2Cl2), diethyl ether (Et2O) and ethyl 
acetate (AcOEt) were purchased from Merck 
(Darmstadt, Germany). Ammonium acetate (AcONH4) 
was purchased from Carlo Erba (Milano, Italy). 
Deionised water was produced by a Milli-Q Milli-pore 
De Vito Virginia et al. / American Journal of Animal and Veterinary Sciences 2015, 10 (2): 91.100 
DOI: 10.3844/ajavsp.2015.91.100 
 
93 
Water System (Millipore, MA, USA). Formic acid 
(HCOOH) was purchased from Sigma-Aldrich 
(Steinheim, Germany). All other reagents and materials 
were of analytical grade and supplied from commercial 
sources. The LC mobile phase were filtered through 0.2 
µm cellulose acetate membrane filters (Sartorius Stedim 
Biotech S.A., Aubagne Cedex, France) with a solvent 
filtration apparatus. 
Standard Solutions 
Singular stock solutions of FLU and IS in water were 
prepared, at a concentration of 500 µg mL
−1
 and 1000 
µg/mL respectively, using volumetric flasks. These 
solutions were successively diluted (water) to reach final 
concentrations of 1, 10, 20, 50, 100, 200, 500, 1000 and 
2500 ng/mL for FLU and 5, 10, 20, 50, 100 and 250 
µg/mL for the IS. These were stored at −20°C. Canine 
drug-free plasma was provided by the blood bank of the 
Veterinary Hospital of the University of Pisa. It was spiked 
with the following FLU concentrations 1, 10, 100, 200, 500 
and 1000 ng/mL. The calibration curve was obtained using 
the six known spiked samples above mentioned and was 
based on analyte/IS peak area ratios. Correlation 
coefficients for the calibration curves were r
2
>0.98. 
Sample Extraction 
The procedure was performed in a 15 mL 
polypropylene vial. A 500 µL aliquot of plasma sample 
was added to 100 µL of IS (100 µg mL
−1
) and vortexed for 
60 sec. Four mL of AcOEt:CH2Cl2 (7:3v/v) were added, 
then the sample was vortexed (30 sec), shaken (100 
osc/min, 10 min) and centrifuged at 3,000 g for 10 min at 
10°C. Three mL of the supernatant were collected in a 
separate vial. The organic phase was evaporated under a 
gentle stream of nitrogen at 40°C and reconstituted with 
500 µL of the mobile phase. Twenty µL of this latter 
solution were injected onto the HPLC-FL. 
Bioanalytical Method Validation 
The described method was validated in terms of 
linearity, Limit Of Detection (LOD), Limit Of 
Quantification (LOQ), recovery, specificity, stability, 
precision and accuracy according to international guidelines 
on the bioanalytical method validation (Anonymus, 2011). 
Within-run and between-run accuracy and precision 
were assessed on quality control samples (QC samples) 
and determinated by replicate analyses using 3 
determinations of different concentration levels: LOQ (1 
ng/mL), low QC (50 and 100 ng/mL), medium QC (500 
ng/mL) and high QC (1000 ng/mL). 
Stability studies were performed to ensure good 
reproducibility of the method. Stock solution of the 
analyte and IS (10 µg/mL) and high and low QC samples 
were tested for short-term room temperature conditions, 
long term storage conditions (−20°C) and freeze–thaw 
stability. Short-term stability determinations were 
obtained by thawing the QC samples and keeping them 
at room temperature for 24 h, whereas long-term stability 
was assessed by storing the samples for a period of 30 
days at −20°C. 
Animal Treatment and Sampling 
Blood samples were obtained from two healthy 
female adult dogs administered with a single oral dose of 
FLU (5 mg kg
−1
) after a 12 h overnight fasting period. 
Accurate dosing was achieved by partitioning the 
commercially available hard capsules (Efiret
®
 100 mg 
hard capsules, FLU maleate, Meda Pharma S.p.A. 
Milano, Italy). The blood (2-3 mL) was collected via 
indwelling catheter previously inserted in the left jugular 
vein, at assigned times (0, 15, 30, 45 min and 1, 1.5, 2, 3, 
4, 5, 6, 8, 10 and 24 h). The study protocol was approved 
by the University of Pisa’s ethics committee for animal 
welfare (CEASA) and transmitted to the Italian Ministry 
of Health (protocol # 0014896). 
Quantification 
When unknown samples were assayed, a blank and a 
fortified blank sample were processed simultaneously for 
quality control. LOD and LOQ were determined as 
analyte concentrations giving signal-to-noise ratios of 3 
and 10, respectively. 
Statistical Analysis and Pharmacokinetic 
Evaluation 
The statistical analyses were evaluated using the 
Student’s t-test. The results were presented as mean ± 
Standard Deviation (SD). In all the experiments, 
differences were considered significant if the associated 
probability level (P) was lower than 0.05. The 
pharmacokinetic calculations were carried out by Win-
Nonlin v 5.2.1 (Pharsight Corp, Sunnyvale, CA, USA), 
using the standard non-compartmental analysis. 
Results 
Detection Method Development 
Derivation of the method was obtained by combining 
data from early studies (Obermeier et al., 1985; 
Narang et al., 1984), with some modifications. Two 
mobile phases were preliminarily tested (water + 
formic acid [200:1 v:v]:ACN, 40:60 v/v; AcONH4[20 
mM]:ACN, 40:60 v/v). The latter mobile phase with a 
1.0 mL/min flow rate was found to optimally provide 
separation between FLU, IS and matrix interference 
peaks. A range of buffer pH (4.0, 5.0, 6.0, 6.8) were 
tried to optimize the chromatographic separation. The 
retention time of FLU was insensitive to pH showing 
negligible variations. The IS was influenced by 
different pH (Fig. 2). 
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Fig. 2. Effect of the pH on the retention time of FLU (gray bars) 
and IS (white bars) 
 
At pH 6 the peak was flatter than those found at pH 6.8; 
at pH 5 an almost complete overlapping of FLU and IS 
peaks was shown; at pH 4 the IS peak moved to a 
retention time of 2.9 min, overlapping the matrix peaks. 
A pH value of 6.8 provided the best separation between 
the FLU, IS and matrix peaks. These analytical 
conditions were an excellent compromise in terms of 
sensitivity, peak separation and backpressure (125 bar). 
A full scan of pure FLU and IS by the fluorescence 
detector showed the values of 323 and 370 nm as the 
optimal excitation and emission wavelenghts for the two 
compounds, respectively. 
Three compounds (retigabine, metoclopramide and 
trazodone) with amenable chemical features were evaluated 
as ISs. Among these, trazodone was found to be the best 
candidate with an excellent resolution and a suitable 
retention time, providing the shortest chromatographic 
course and with peaks well distinct and separated from both 
the FLU peak and matrix interferences (Fig. 3). On the 
other hand, retigabine, the most similar to FLU in chemical 
and physical characteristics, showed partial overlap with 
FLU, especially at high concentrations. Metoclopramide 
was not well separated from the interferences due to the 
matrix (data not shown). 
Optimization of the Extraction Method 
Solvents such as AcOEt, CH2Cl2 and Et2O were 
examined. AcOEt and CH2Cl2 were selected as the most 
suitable organic solvents in terms of analyte extraction 
and minimization of matrix components. Variations in 
the proportions of the selected extraction solvents 
(AcOEt:CH2Cl2, 7:3, 3:7, 3:2, v/v) were also assessed in 
terms of recovery and selectivity. AcOEt:CH2Cl2, 7:3 v/v 
showed the best recovery for FLU (range 82-89%) and 
the IS (77.41±9.82%) (Table 1). 
Method Validation 
It was necessary to validate each step in the analytical 
method because to date, methodology for the 
determination of FLU from canine plasma samples 
through a fluorimetric detector is yet to be published. 
The calibration curves were constructed by plotting the 
ratio of the peak areas versus concentrations in the 
working range of 1-1000 ng/mL. The calibration 
equation was Y=9980X-36800 and the correlation 
coefficient was r
2
=0.980. A good linearity was achieved 
in the investigated range of 1-1000 ng/mL for FLU. 
According to EMA guidelines, LOD and LOQ were 
calculated based on signal-to noise approach. The typical 
signal-to-noise ratios were 10:1 and 3:1 for LOQ and 
LOD, respectively. Both the trueness and the precision 
of these values lay within the proposed criteria (RSD%, 
<20%). The specificity was investigated in regard to the 
other co-eluting components by comparing the 
chromatograms of different batches of blank matrices to 
those from spiked plasma solutions and test samples. It 
was found that under optimized chromatographic 
conditions, peaks due to the matrix did not interfere with 
FLU and IS (Table 2). Typical retention times for FLU and 
IS was 4.6±0.2 and 5.8±0.2 min, respectively (Fig. 3). The 
trueness (94.14%) was evaluated by determining the 
recovery for five replicates of the QC samples (Table 2). 
The FLU recovery ranged from 89.30% to 82.97%. The 
LOQ was 1 ng/mL: it has been considered excellent 
for determining the pharmacokinetic profiles of FLU 
(Chen et al., 2001). The CV% value was 4.47%. Intra-
day value consistency (repeatability) was evaluated 
for three replicates of the QC samples during the same 
day (3.7-4.1%) (Table 3). Inter-day value consistency 
(intermediate precision) was evaluated by 
quantization of FLU in QC samples on three different 
days (0.6-4.8%) (Table 4). Relative errors for both the 
intra-day and inter-day trueness were <5%.  
Short term stability (room temperature) showed a 
CV% 3.9%. Data obtained after three freeze-thaw cycles 
showed that FLU was stable in dog plasma (CV%, <5%). 
Robustness of the methodology was determined by the 
reproducibility of results using the analytical method in 
different laboratories or under different circumstances. 
The present study evaluated three plasma aliquots from 
the treated dogs in two different labs (Department of 
Surgical, Medical, Molecular Pathology and Critical Area, 
University of Pisa, Italy) and obtained variations of less 
than 7.2%. The validation parameters were in agreement 
with the EMA guidelines (Anonymus, 2011). 
HPLC-MS Analysis 
The selectivity of the method was also confirmed by 
HPLC-MS analysis of plasma samples collected in treated 
dogs. No compounds co-eluting with the analyte of interest 
were detected by full scan acquisitions in positive ion mode. 
This is particularly demonstrated from the HPLC-MS 
extracted ion chromatogram (m/z 305 and 372 Da for FLU 
and IS, respectively) that exhibited a good correspondence 
with the HPLC–FL chromatogram. Retention times of both 
FLU and IS were not substantially altered (4.70±0.2 and 
5.85±0.3 min for FLU and IS respectively) (Fig. 4).
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  (B) 
 
 
 (C) 
 
Fig. 3. Chromatographic curve by HPLC-FL. (A) Chromatographic curve from canine control plasma. (B) Chromatographic curve 
from fortified sample (FLU 50 ng/mL; IS 10 µg/mL). (C) Chromatographic curve from plasma sample collected in a dog (6h) 
orally administered with FLU (5 mg kg
−1
) 
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Fig. 4. HPLC-MS extracted ion chromatogram. It was acquired from a real sample and is relative to the ions at m/z 305 and 372 Da. The 
peaks from FLU and IS, clearly shown at 4.70 min and 5.85 min, respectively, confirm a good correspondence between HPLC 
 
 
 
Fig. 5. Mass spectrum in positive ion mode. Spectrum obtained from the analyte peak at 4.70 min. A real sample [5 mg kg
−1
 
treated dog (1 h)] acquired in positive ion mode 
 
 
 
Fig. 6. Mean concentration-time curve of FLU after a single oral dose (5 mg kg−1) of Efiret® in 2 adult dogs 
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Table 1. Extraction recovery % (±SD) of FLU and IS spiked at 10, 50, 100 ng/mL of FLU and 10 µg/mL of IS  
 Recovery % 
 ------------------------------------------------------------------------------------------------------------------------------------
   FLU  IS 
Organic solvents v/v ratio 10ng/mL 50ng/mL 100ng/mL 10µg/mL 
AcOEt:CH2Cl2 7:3 89.30±13.76 85.70±4.54 82.97±11.39 77.41±9.82 
AcOEt:CH2Cl2 3:7 47.06±12.12 42.07±4.60 51.27±3.28 40.11±7.22 
AcOEt:CH2Cl2 3:2 71.97±1.69 78.69±9.36 65.84±4.27 62.80±11.97 
 
Table 2. Summary of validation data for FLU 
Property Units Flupirtine 
Linear range  ng/mL 1-1000 
Calibration equation  Y=9980X-36800 
Correlation coefficient  r2 0.980±0.0594 
LOQ  ng/mL 1 
LOD  ng/mL 0.3 
Trueness % 94.14 
Precision % 
Inter-day   0.6-4.8 
Intra-day  3.7-4.1 
Specificity   Specific 
 
Table 3. Intra-day values of FLU 
Concentration level (%) Spiked concentration (ng/mL) Concentration obtained (ng/mL) Mean repeatability (%) 
 1 0.95 
1 1 0.98 95.9 
 1 0.94 
 50 50.7 
50 50 51.6 100.8 
 50 49.0 
 100 101.2 
100 100 102.6 101.3 
 100 103.0 
 500 487.5 
500 500 501.0 99.9 
 500 510.0 
 1000 1029 
1000 1000 1040 103.7 
 1000 1042 
 
Table 4. Inter-day values of FLU 
Concentration level (%) Spiked concentration (ng/mL) Concentration obtained (ng/mL)§ Mean repeatability (%) 
 1 (day 1) 0.99, 1.0, 0.98 
1 1 (day 2) 0.98, 1.0, 0.99 99.4 
 1 (day 3) 1.0, 0.97, 1.03 
 50 (day 1) 50.6, 49.8, 50.9 
50 50 (day 2) 47.8, 49.4, 49.6 100.8 
 50 (day 3) 52.1, 51.6, 50.6 
 100 (day 1) 108.9, 109.5, 108.2 
100 100 (day 2) 103.6, 104.2, 103.0 104.8 
 100 (day 3) 100.9, 101.6, 100.2 
 500 (day 1) 527.0, 520.1, 533.9 
500 500 (day 2) 499.5, 500.9, 4.98.1 102.9 
 500 (day 3) 517.0, 515.9, 518.1 
 1000 (day 1) 989.0, 991.5, 986.5 
1000 1000 (day 2) 1041.0, 1039.0, 1037.0 101.7 
 1000 (day 3) 1025.5, 1020.5, 1023.0  
§Each row reports three concentration values obtained in the same day 
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Table 5. Main pharmacokinetic parameters of FLU after a single oral dose (5 mg/kg) of Efiret® in 2 adult dogs 
  Oral 5 mg/kg (n=2) 
  --------------------------------------------------------------------- 
Parameter Units Mean ±SD 
R2  0.99 0.01 
λZ 1/h 0.09 0.03 
T1/2 λZ h 7.48 2.10 
Tmax h 1.75 0.35 
Cmax ug/mL 0.85 0.22 
AUC0-∞ h*ug/mL 4.10 0.29 
Vz/F mL/kg 13066.55 2767.52 
CL/F mL/h/kg 1222.83 86.89 
MRT h 8.50 2.62 
R2, correlation between observed/predicted points; λz, the rate constant associated with the terminal elimination phase;T1/2λZ, half-
life of the elimination phase; Tmax, time of peak; Cmax, peak plasma concentration; AUC0–∞, area under the plasma concentration–
time curve extrapolated to infinity; CL/F, apparent clearance; Vz/F, apparent volume of distribution; MRT, mean resident time 
 
Moreover, mass spectra in positive ion mode showed 
only one significant ion at m/z 305.2 Da, confirming 
that FLU is the only compound responsible for the 
peaks at 4.70 min (Fig. 5). This ion, as confirmed by 
further MS–MS experiments, is the pseudo molecular 
ions ([M
+
H]
+
) of FLU.  
The peak at 2.5 min reported in Figure 3c has not any 
fragmentation similar to FLU (data not shown). Hence, it 
has been concluded that it is an artefact due to the 
individual dog matrix. 
Application of the Method  
The applicability of this method has been verified by 
determining FLU in canine plasma after single oral 
treatment with 5 mg kg
−1
 of Efiret
®
. HPLC analysis of the 
plasma confirmed the presence of FLU in time related 
amounts (Fig. 6). The average FLU concentration in 
plasma ranged between 4.3 and 760 ng/mL. The described 
method allowed monitoring of the concentration versus 
time curves of the analyte and the calculation of the basic 
pharmacokinetic parameters (Table 5).  
Discussion 
A number of analytical methods have been employed 
for the detection of FLU, mostly in biological matrices. 
Obermeier et al. (1985) used the HPLC-UV to assess the 
pharmacokinetic profile of FLU. Unfortunately in that 
study, the lack of both method validation and 
determination of key parameters (i.e., LOQ, recovery, 
accuracy, etc) prevents a comparison with the present 
method. The two HPLC-FL methods present in the 
literature (Niebch et al., 1992; Narang et al., 1984) are 
partially validated. They reported only some of the key 
parameters requested by the EMA guidelines (Anonymus, 
2011) and showed longer chromatographic curves then the 
present study. The LOQ detected in the present study was 
lower than those reported in the previous HPLC-FL 
methods (Niebch et al., 1992; Narang et al., 1984). In 
contrast, methods carried out with expensive devices such 
as LC MS-MS with Atmospheric Pressure Chemical 
Ionization (APCI) (Chen et al., 2001), Electrospray 
Ionization (ESI) (Zhong et al., 2001; Kandasamy et al., 
2011) and Ultra-Performance Liquid Chromatography 
(UPLC) (Satheesh et al., 2012) showed comparable values 
of selectivity, accuracy, precision, stability and specificity 
to those found in this study. The findings concerning short 
and long term stability indicated that the room temperature 
and storage of analyte in plasma samples at −20° C is 
adequate and no stability-related problems would be 
expected during routine analyses for pharmacokinetic 
study. The results of the validation parameters 
demonstrated that the method enables accurate 
quantification of FLU. Narang et al. (1984) 
simultaneously detected FLU and its acetylate metabolite 
in human plasma. However, the reported LOQ for this 
metabolite was 200 ng/mL, too high to determine its 
pharmacokinetic profile after oral administration. 
According to our preliminary LC-MS-MS no other 
significant amount of compounds structurally related to 
FLU has been detected in dog-treated plasma samples 
(data not shown). It is likely that the metabolic patter 
between human and dog may differ quantitatively and/or 
qualitatively (Lin and Lu, 1997). This discrepancy might 
be due to the earlier proven metabolic interspecies 
differences (Martignoni et al., 2006). However, further ad 
hoc studies need to clarify this issue and pharmacokinetic 
data have to be considered with the caveat that they are 
based on measurements from two dogs only and should be 
integrated with further studies in this animal species. 
Conclusion 
The analytical method described in this work is fully 
validated in canine plasma according to the EMA 
guidelines (Anonymous, 2011). It provides selective and 
accurate analysis of FLU without the need for expensive 
clean-up steps, solvent consuming flows or expensive 
devices. The low LOQ shows that the method could be 
useful for drug measurement even when administered in 
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sub-clinical doses. As FLU is a drug recently considered 
for the veterinary medicine application, this method is the 
most suitable to be used for pharmacokinetic 
investigations in canines. In summary, this is the first time 
that a HPLC-FL technique is validated for determination 
and quantification of FLU in canine plasma.  
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